Frøling Malte, Mikkelsen Clara, Eggertsen Peter Preben, Stern Mette, van de Looij Anne, Deleuran Bent
Ugeskr Laeger. 2017 Oct 30;179(44).
Rheumatoid arthritis (RA) is a chronic inflammatory joint disease. The introduction of a new class of disease-modifying anti-rheumatic drugs, which work by inhibiting the Janus kinase-signal transducer and activator of transcription (JAK/STAT) pathway, has led to new possibilities for achieving remission of RA. Tofacitinib and baricitinib are both JAK/STAT inhibitors, which have shown efficacy in line with anti-tumour necrosis factor treatment. The side effects seem manageable, and up to now only increased risk of herpes zoster has raised consideration. JAK/STAT inhibitors create new possibilities for reaching low disease activity or remission for patients with RA.
类风湿性关节炎（RA）是一种慢性炎症性关节疾病。一类新的改善病情抗风湿药物的引入为实现类风湿性关节炎缓解带来了新的可能性，这类药物通过抑制Janus激酶-信号转导子和转录激活子（JAK/STAT）途径发挥作用。托法替布和巴瑞替尼都是JAK/STAT抑制剂，它们已显示出与抗肿瘤坏死因子治疗相当的疗效。副作用似乎可控，到目前为止，只有带状疱疹风险增加引起了关注。JAK/STAT抑制剂为类风湿性关节炎患者实现低疾病活动度或缓解创造了新的可能性。
